Tumor microenvironment-derived IL-32 promotes aggressive phenotypes and stem cell traits in head and neck squamous cell carcinoma

肿瘤微环境来源的IL-32促进头颈部鳞状细胞癌的侵袭性表型和干细胞特性。

阅读:2

Abstract

BACKGROUND/PURPOSE: Head and neck squamous cell carcinoma (HNSCC) is an aggressive malignancy distinguished by marked invasiveness, a high metastatic propensity, and poor prognosis. Cancer-associated fibroblasts (CAFs) within the tumour microenvironment secrete numerous mediators that accelerate tumour progression; however, the precise contribution of CAF-derived interleukin-32 (IL-32) remains unclear. This study examined the influence of CAF-derived IL-32 on invasion, epithelial-mesenchymal transition (EMT), and cancer-stem-cell (CSC) traits in HNSCC. MATERIALS AND METHODS: Primary CAFs and normal fibroblasts (NFs) were isolated from HNSCC specimens. IL-32 expression was quantified by microarray analysis, quantitative PCR, Western blotting, and enzyme-linked immunosorbent assay. Migration and invasion of FaDu and SCC25 cells were assessed with Transwell assays after exposure to CAF-conditioned medium or recombinant IL-32. EMT markers were evaluated by Western blotting, whereas sphere-formation assays and flow cytometry for CD133(+)/CD44(+)/CD24(+) populations were used to determine stemness. RESULTS: IL-32 was significantly up-regulated in CAFs compared with NFs. Both CAF-conditioned medium and recombinant IL-32 markedly increased the migratory and invasive capacities of HNSCC cells. These treatments reduced E-cadherin and increased Vimentin, Snail, and Twist expression, while enhancing sphere formation and expanding CD24(+), CD44(+) and CD133(+) sub-populations. CONCLUSION: CAFs promote HNSCC progression through IL-32-mediated enhancement of invasion, EMT induction, and CSC properties. Targeting IL-32 signalling may represent a promising therapeutic approach to improve outcomes in HNSCC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。